US EditionGSK CEO Emma Walmsley Says Drugmaker Is ‘Betting Big’ on the US
6 Articles
6 Articles
A pharma C-suite shakeup and Trump's deal with Pfizer
How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more on this week’s episode of “The Readout LOUD,” a weekly biotech podcast from STAT. Read the rest…
GSK CEO Emma Walmsley Says Drugmaker Is ‘Betting Big’ on the US
GSK Plc is “betting big on the US” and engaged in constructive talks on drug pricing with US President Donald Trump’s administration, according to Emma Walmsley, the outgoing chief executive officer of the British drugmaker.
Singular Market Consensus Bank The English pharmaceutical company has announced that it is betting enormously on the US and, as its rival Pfizer has already done, has had constructive talks on drug prices with the Trump Administration. Today it raises the pharmaceutical sector as investors understand that it is a constructive dialogue between industry and government, and the country is for the majority of big pharmaceuticals its main market and…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
